Related Experiment Video
Updated: Sep 11, 2025

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
Published on: July 16, 2012
Repurposing metabolic drugs as anti-inflammatory agents
Andrew E Hogan1, Cian Davis2, Benjamin J Jenkins3
1Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co Kildare, Ireland.
None:
Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-like peptide-1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have entered the clinical management of bodyweight and metabolic disease with great success. With their expanded use, it is emerging that the benefits of these drugs extend beyond metabolic improvements into changes in chronic inflammation, potentially independent of those in metabolism. In this review, we discuss the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders and beyond. We highlight the molecular mechanisms via which these drugs exert their anti-inflammatory actions and discuss their potential repurposing as direct anti-inflammatory agents.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drug Biotransformation: Overview
Drugs for Treatment of Ulcerative Colitis in IBD

